top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

29.98 -5.77 (-16.13%)
Streaming Delayed Price Updated: 1:58 PM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,221,314
Open 31.68
Bid (Size) 29.89 (100)
Ask (Size) 30.06 (200)
Prev. Close 35.74
Today's Range 29.86 - 33.03
52wk Range 29.70 - 50.79
Shares Outstanding 32,250,236
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Collegium Pharmaceutical Q2 Earnings Call Highlights ↗
Collegium Pharmaceutical (NASDAQ:COLL) reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower... 
Via MarketBeat
Topics Earnings
Collegium Pharmaceutical (NASDAQ:COLL) Tumbles on Revenue Miss and Lowered Guidance ↗
Via Chartmill

Performance

YTD
-34.2%
-34.2%
1 Month
-20.0%
-20.0%
3 Month
-17.9%
-17.9%
6 Month
-37.8%
-37.8%
1 Year
-3.6%
-3.6%

More News

Read More
News headline image
Collegium Pharmaceutical (NASDAQ:COLL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops
Via StockStory
News headline image
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
Via StockStory
Collegium Pharmaceutical (NASDAQ:COLL) Surges on Q1 Earnings Beat as JORNAY PM Revenue Jumps 36% ↗
Via Chartmill
Topics Earnings
News headline image
Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
1 Healthcare Stock with Competitive Advantages and 2 We Question
Via StockStory
News headline image
1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm
Via StockStory
News headline image
1 Mooning Stock to Own for Decades and 2 That Underwhelm
Via StockStory
News headline image
2 Profitable Stocks to Keep an Eye On and 1 We Brush Off
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks We Approach with Caution
Via StockStory
News headline image
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
2 Reasons to Sell COLL and 1 Stock to Buy Instead
Via StockStory
Topics Supply Chain
News headline image
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
3 Growth Stocks We’re Skeptical Of
Via StockStory
News headline image
Collegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
Via StockStory
Topics Economy
News headline image
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
1 Healthcare Stock with Competitive Advantages and 2 We Brush Off
Via StockStory
News headline image
COLL Q1 Deep Dive: ADHD Portfolio Expansion and Pain Segment Stability Drive Results
Via StockStory
News headline image
Collegium (COLL) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 CY2026 Expectations, Stock Soars
Via StockStory

Frequently Asked Questions

Is Collegium Pharmaceutical, Inc. - Common Stock publicly traded?
Yes, Collegium Pharmaceutical, Inc. - Common Stock is publicly traded.
What exchange does Collegium Pharmaceutical, Inc. - Common Stock trade on?
Collegium Pharmaceutical, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Collegium Pharmaceutical, Inc. - Common Stock?
The ticker symbol for Collegium Pharmaceutical, Inc. - Common Stock is COLL on the Nasdaq Stock Market
What is the current price of Collegium Pharmaceutical, Inc. - Common Stock?
The current price of Collegium Pharmaceutical, Inc. - Common Stock is 29.98
When was Collegium Pharmaceutical, Inc. - Common Stock last traded?
The last trade of Collegium Pharmaceutical, Inc. - Common Stock was at 08/06/26 01:58 PM ET
What is the market capitalization of Collegium Pharmaceutical, Inc. - Common Stock?
The market capitalization of Collegium Pharmaceutical, Inc. - Common Stock is 966.70M
How many shares of Collegium Pharmaceutical, Inc. - Common Stock are outstanding?
Collegium Pharmaceutical, Inc. - Common Stock has 967M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page